Advertisement

Topics

Janus Company Profile

10:55 EDT 22nd June 2018 | BioPortfolio

We offer a broad range of investment options, but our expertise is in growth and risk-managed funds. Some of us are driven by a never-ending search for an information advantage. Others by an unwavering pursuit of a statistical advantage. Together, however, our goal is to deliver strong, long-term results to our shareholders. Learn more about us and how we invest.

Location

P.O. Box 173375
Denver
Colorado
80217-3375
United States of America

Contact

Phone: 800.525.3713


News Articles [40 Associated News Articles listed on BioPortfolio]

Janus Kinase Inhibitors: Emerging Applications in Dermatology

Learn about the use of Janus kinase inhibitors, which have become promising treatment options for dermatologic conditions such as psoriasis, atopic dermatitis, alopecia areata, vilitigo, and more. S...

Mylan (MYL) Stake Boosted by Janus Henderson Group PLC

Janus Henderson Group PLC lifted its holdings in Mylan by 56.5% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 114,620 shares of the company's ...

Global and Chinese Cancer Janus Kinase Inhibitor Industry, 2017 Market Research Report [Report Updated: 20122017] Prices from USD $3000

The 'Global and Chinese Cancer Janus Kinase Inhibitor Industry, 20122022 Market Research Report' is a professional and indepth study on the current state of the global Cancer Janus Kinase Inhibitor in...

Janus Kinase JAK Inhibitor Pipeline Insight, 2018 [Report Updated: 14022018] Prices from USD $1250

Janus Kinase JAK Inhibitor Pipeline Insight, 2018 report by DelveInsight offers comprehensive insights of the pipeline under development therapeutics scenario and growth prospects across Janus Kinase...

Janus Kinase 1 JAK1 Inhibitor Pipeline Insight, 2018 [Report Updated: 14022018] Prices from USD $1500

Janus Kinase 1 JAK1 Inhibitor Pipeline Insight, 2018 report by DelveInsight offers comprehensive insights of the pipeline under development therapeutics scenario and growth prospects across Janus Kin...

Janus Kinase 3 JAK3 Inhibitor Pipeline Insight, 2018 [Report Updated: 14022018] Prices from USD $1250

Janus Kinase 3 JAK3 Inhibitor Pipeline Insight, 2018 report by DelveInsight offers comprehensive insights of the pipeline under development therapeutics scenario and growth prospects across Janus Kin...

FDA approves Pfizer's Xeljanz for ulcerative colitis

The oral therapy is the first and only Janus kinase (JAK) inhibitor approved in the US for this patient population

Author Correction: Chemical Adsorption and Physical Confinement of Polysulfides with the Janus-faced Interlayer for High-performance Lithium-Sulfur Batteries

Drugs and Medications [0 Results]

None

PubMed Articles [86 Associated PubMed Articles listed on BioPortfolio]

Preparation of polymeric Janus microparticles with hierarchically porous structure and enhanced anisotropy.

Anisotropic Janus particles are of great interest for many applications. It is well known that behavior and utility of Janus particles are highly dependent on their chemistry and geometry. Herein, we ...

Simultaneous two drugs release form Janus particles prepared via polymerization-induced phase separation approach.

Seeded emulsion polymerization of 2-dimethylaminoethylamino methacrylate (DMAEMA) was carried out using monodispersed poly(2-hydroxyehtyl methacrylate) (PHEMA) seeds to produce Janus particles. Three ...

Curvature-mediated assembly of Janus nanoparticles on membrane vesicles.

Besides direct particle-particle interactions, nanoparticles adsorbed to biomembranes experience indirect interactions that are mediated by the membrane curvature arising from particle adsorption. In ...

Electrospun Hydrophilic Janus Nanocomposites for the Rapid Onset of Therapeutic Action of Helicid.

The oral delivery of active ingredients for the fast onset of therapeutic effects is a well-known method in patients. In this study, a new kind of hydrophilic Janus structural nanocomposites was desig...

Janus Iron Oxides @ Semiconducting Polymer Nanoparticle Tracer for Cell Tracking by Magnetic Particle Imaging.

Iron oxides nanoparticles tailored for magnetic particle imaging (MPI) have been synthesized, and their MPI signal intensity is 3 times of commercial MPI contrast (Ferucarbotran, also called Vivotrax)...

Clinical Trials [12 Associated Clinical Trials listed on BioPortfolio]

A Single Center Prospective Randomized Controlled Clinical Study of JANUS Stent in Patients With Coronary Artery Disease

Janus stent is the only marketed drug-eluting stent (DES) without polymer coating as yet in China. The goal of this study is to evaluate the efficacy of JANUS (Tacrolimus eluted stent) i...

This is a Study to Determine the Effect and Safety of an Oral Janus Kinase 2 (JAK2)-Inhibitor in Patients With Multiple Myeloma

The purpose of this study is to determine clinical efficacy and safety of INCB018424, a small molecule Janus kinase (JAK) inhibitor, in patients with refractory or relapsed multiple myelom...

Study of Tofacitinib in Refractory Dermatomyositis

The purpose of this study is to obtain preliminary data regarding the safety and efficacy of Janus kinase (JAK) inhibitor, tofacitinib, in adults with active, treatment-refractory dermatom...

Assessing an Oral Janus Kinase Inhibitor, AZD4205, in Combination With Osimertinib in Patients Who Have Advanced Non-small Cell Lung Cancer

This study will treat patients with advanced NSCLC who have progressed following prior therapy. This is the first time this drug has ever been tested in patients, and so it will help to un...

A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects With Crohn's Disease Who Completed the Studies M14-431 or M14-433

A multicenter study to evaluate the efficacy and safety of maintenance and long-term treatment administration of upadacitinib, an orally administered Janus kinase 1 inhibitor, in adult par...

Companies [3 Associated Companies listed on BioPortfolio]

Janus Pharmaceuticals, Inc

Janus was founded in 2004 by Catalyst Pharma Group Inc. (CPG), a clinical development services company in the United States and aRigen, Inc., a private equity backed bio-medical venture company in Jap...

Janus

We offer a broad range of investment options, but our expertise is in growth and risk-managed funds. Some of us are driven by a never-ending search for an information advantage. Others by an unwaverin...

Blum Capital Partners

Blum Capital Partners, which is headquartered in San Francisco, utilizes private equity and strategic block transactions to invest in both public and private companies.A representative sample of our i...

More Information about "Janus" on BioPortfolio

We have published hundreds of Janus news stories on BioPortfolio along with dozens of Janus Clinical Trials and PubMed Articles about Janus for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Janus Companies in our database. You can also find out about relevant Janus Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record